Zacks Research Predicts OPKO Health FY2027 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of OPKO Health in a research report issued on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the biotechnology company will earn ($0.09) per share for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

OPK has been the subject of a number of other reports. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, March 19th. Finally, Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.80 on Monday. OPKO Health has a twelve month low of $0.99 and a twelve month high of $2.04. The business has a 50 day simple moving average of $1.66 and a 200-day simple moving average of $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -9.47 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock in a transaction on Friday, January 17th. The shares were purchased at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the acquisition, the chief executive officer now owns 213,186,477 shares in the company, valued at approximately $313,384,121.19. This represents a 0.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 964,971 shares of company stock worth $1,493,692 in the last quarter. Insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of OPKO Health by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 8,064 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after purchasing an additional 8,396 shares during the period. FMR LLC increased its stake in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,417 shares during the period. Finally, Comerica Bank raised its holdings in OPKO Health by 18.2% during the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock worth $156,000 after buying an additional 16,369 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.